{"url_path":"/sec/vera/8-k/2026-07-09/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-09","source_url":"https://www.sec.gov/Archives/edgar/data/1831828/0001193125-26-299165-index.html","accession_number":"0001193125-26-299165","cik":"0001831828","ticker":"VERA","issuer_name":"Vera Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1831828/0001193125-26-299165-index.html","primary_entity_key":"0001831828","primary_entity_name":"Vera Therapeutics, Inc."},"word_count":129,"has_tables":true,"body_markdown":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\nOn July 9, 2026, Vera Therapeutics, Inc. (the “Company”) announced that William Turner will no longer serve as the Company’s Chief Regulatory Officer and will transition to the role of Special Advisor for Regulatory Affairs, effective as of August 3, 2026. Nancy Bowman, M.D., Ph.D., will succeed Mr. Turner as the Company’s Chief Regulatory Officer, effective as of August 3, 2026.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nVera Therapeutics, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nJuly 9, 2026\n\nBy:\n\n/s/ Marshall Fordyce\n\n \n\n \n\n \n\nMarshall Fordyce, M.D.\nChief Executive Officer"}